MX387719B - Biomarcadores de la enfermedad del hígado graso no alcohólico (nafld) y la esteatohepatitis no alcohólica (nash) y usos de estos. - Google Patents
Biomarcadores de la enfermedad del hígado graso no alcohólico (nafld) y la esteatohepatitis no alcohólica (nash) y usos de estos.Info
- Publication number
- MX387719B MX387719B MX2018012654A MX2018012654A MX387719B MX 387719 B MX387719 B MX 387719B MX 2018012654 A MX2018012654 A MX 2018012654A MX 2018012654 A MX2018012654 A MX 2018012654A MX 387719 B MX387719 B MX 387719B
- Authority
- MX
- Mexico
- Prior art keywords
- alcoholic
- nafld
- nash
- liver disease
- fatty liver
- Prior art date
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title abstract 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title abstract 4
- 239000000090 biomarker Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 230000001476 alcoholic effect Effects 0.000 abstract 1
- 230000007863 steatosis Effects 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787967P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/022547 WO2014150198A2 (en) | 2013-03-15 | 2014-03-10 | Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX387719B true MX387719B (es) | 2025-03-18 |
Family
ID=50483498
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012654A MX387719B (es) | 2013-03-15 | 2014-03-10 | Biomarcadores de la enfermedad del hígado graso no alcohólico (nafld) y la esteatohepatitis no alcohólica (nash) y usos de estos. |
| MX2015011756A MX360140B (es) | 2013-03-15 | 2014-03-10 | Biomarcadores de la enfermedad del higado graso no alcoholico (nafld) y la esteatohepatitis no alcoholica (nash) y usos de estos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011756A MX360140B (es) | 2013-03-15 | 2014-03-10 | Biomarcadores de la enfermedad del higado graso no alcoholico (nafld) y la esteatohepatitis no alcoholica (nash) y usos de estos. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9612248B2 (https=) |
| EP (3) | EP3296747B1 (https=) |
| CN (2) | CN108957006B (https=) |
| BR (1) | BR122019026188B1 (https=) |
| DK (1) | DK3296747T3 (https=) |
| ES (3) | ES2773999T3 (https=) |
| MX (2) | MX387719B (https=) |
| WO (1) | WO2014150198A2 (https=) |
| ZA (1) | ZA201506441B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160289762A1 (en) | 2012-01-27 | 2016-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for profiliing and quantitating cell-free rna |
| HK1211624A1 (en) | 2012-01-27 | 2016-05-27 | The Board Of Trustees Of The University Of The Leland Stanford Junior University | Methods for profiling and quantitating cell-free rna |
| WO2014150198A2 (en) * | 2013-03-15 | 2014-09-25 | Somalogic, Inc. | Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| EP3303629A1 (en) * | 2015-06-05 | 2018-04-11 | Regulus Therapeutics Inc. | Non-alcoholic fatty liver disease biomarkers |
| US20210215711A1 (en) * | 2016-02-08 | 2021-07-15 | Somalogic, Inc. | Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses Thereof |
| US20190071795A1 (en) * | 2016-03-09 | 2019-03-07 | Molecular Stethoscope, Inc. | Methods and systems for detecting tissue conditions |
| CN107630084A (zh) * | 2016-07-18 | 2018-01-26 | 昆山德诺瑞尔生物科技有限公司 | 非酒精性脂肪性肝炎的多基因组合检测试剂盒 |
| JP6893406B2 (ja) * | 2016-10-19 | 2021-06-23 | 日本化薬株式会社 | Ｎａｓｈやｎａｆｌｄの進展度の検査方法及び炎症疾患や癌の検査方法 |
| JP7111322B2 (ja) | 2016-12-02 | 2022-08-02 | 国立大学法人 東京大学 | 線維化関連分子に対する抗体およびその医療応用 |
| JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト |
| US12372530B2 (en) * | 2017-11-15 | 2025-07-29 | Beth Israel Deaconess Medical Center, Inc. | Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis |
| EP3716986A4 (en) * | 2017-12-01 | 2022-02-09 | Cornell University | NANOPARTICLES AND VARIOUS EXOSOME SUBSETS FOR CANCER DETECTION AND TREATMENT |
| WO2020087037A2 (en) * | 2018-10-26 | 2020-04-30 | Molecular Stethoscope, Inc. | Disease stratification of liver disease and related methods |
| GB2615975B (en) | 2019-02-14 | 2023-11-29 | Mirvie Inc | Methods and systems for determining a pregnancy-related state of a subject |
| CN110786834B (zh) * | 2019-12-09 | 2022-04-05 | 中电健康云科技有限公司 | 一种基于舌象特征和bmi指数的脂肪肝预测模型 |
| CN115023615A (zh) * | 2020-01-10 | 2022-09-06 | 私募蛋白质体操作有限公司 | 确定葡萄糖耐量减低的方法 |
| KR20220140727A (ko) * | 2020-02-10 | 2022-10-18 | 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 | 비알코올성 지방간염 (nash) 바이오마커 및 이의 용도 |
| WO2022093757A1 (en) * | 2020-10-30 | 2022-05-05 | The General Hospital Corporation | Kits, reagents and methods for the assessment of liver diseases |
| WO2022114887A1 (ko) * | 2020-11-27 | 2022-06-02 | 국립암센터 | 통합전사체분석 기반 만성 간질환 진단용 복합마커 및 이의 용도 |
| CA3221876A1 (en) | 2021-06-09 | 2022-12-15 | Maxime NACHIT | System and method for determining a risk of having or developing steatohepatitis and/or a complication thereof |
| CN118547066B (zh) * | 2024-07-30 | 2024-11-19 | 上海交通大学医学院附属仁济医院 | 一种非酒精性脂肪性肝炎的诊断试剂盒及诊断系统 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| US6001577A (en) | 1998-06-08 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US5705337A (en) | 1990-06-11 | 1998-01-06 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-SELEX |
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US6458539B1 (en) | 1993-09-17 | 2002-10-01 | Somalogic, Inc. | Photoselection of nucleic acid ligands |
| US6242246B1 (en) | 1997-12-15 | 2001-06-05 | Somalogic, Inc. | Nucleic acid ligand diagnostic Biochip |
| US20070111933A1 (en) * | 2003-06-02 | 2007-05-17 | Kopchick John J | Diagnosis and treatment methods related to aging, especially of liver |
| EP2021512A4 (en) | 2006-05-08 | 2009-08-05 | Tethys Bioscience Inc | SYSTEMS AND METHODS FOR DEVELOPING DIAGNOSTIC TESTS BASED ON BIOMARKER INFORMATION FROM EXISTING CLINICAL SAMPLE ASSEMBLIES |
| US7855054B2 (en) | 2007-01-16 | 2010-12-21 | Somalogic, Inc. | Multiplexed analyses of test samples |
| US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US7824871B2 (en) * | 2007-06-14 | 2010-11-02 | George Mason Intellectual Properties | Methods of diagnosing non-alcoholic steatohepatitis (NASH) |
| CN101802225B (zh) | 2007-07-17 | 2013-10-30 | 私募蛋白质体公司 | 检测样品的多元分析 |
| WO2010000835A1 (en) | 2008-07-03 | 2010-01-07 | One Way Liver Genomics, S.L. | Proteomic fingerprint for the diagnosis of non-alcoholic steatohepatitis (nash) and/or steatosis |
| US20100124548A1 (en) * | 2008-10-29 | 2010-05-20 | University Of Oulu | Pharmaceutical product |
| US20120282276A1 (en) * | 2009-11-05 | 2012-11-08 | The Regents Of The University Of Michigan | Biomarkers predictive of progression of fibrosis |
| SG186953A1 (en) | 2010-07-09 | 2013-02-28 | Somalogic Inc | Lung cancer biomarkers and uses thereof |
| CN103429753A (zh) | 2010-09-27 | 2013-12-04 | 私募蛋白质体公司 | 间皮瘤生物标记及其用途 |
| WO2014074682A1 (en) * | 2012-11-07 | 2014-05-15 | Somalogic, Inc. | Chronic obstructive pulmonary disease (copd) biomarkers and uses thereof |
| WO2014150198A2 (en) * | 2013-03-15 | 2014-09-25 | Somalogic, Inc. | Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof |
-
2014
- 2014-03-10 WO PCT/US2014/022547 patent/WO2014150198A2/en not_active Ceased
- 2014-03-10 CN CN201810800026.2A patent/CN108957006B/zh active Active
- 2014-03-10 ES ES17197260T patent/ES2773999T3/es active Active
- 2014-03-10 EP EP17197260.7A patent/EP3296747B1/en active Active
- 2014-03-10 MX MX2018012654A patent/MX387719B/es unknown
- 2014-03-10 EP EP19206123.2A patent/EP3660512B1/en active Active
- 2014-03-10 CN CN201480022424.6A patent/CN105143887B/zh active Active
- 2014-03-10 EP EP14717266.2A patent/EP2972386B1/en active Active
- 2014-03-10 BR BR122019026188-1A patent/BR122019026188B1/pt active IP Right Grant
- 2014-03-10 ES ES19206123T patent/ES2986657T3/es active Active
- 2014-03-10 DK DK17197260.7T patent/DK3296747T3/da active
- 2014-03-10 US US14/202,714 patent/US9612248B2/en active Active
- 2014-03-10 MX MX2015011756A patent/MX360140B/es active IP Right Grant
- 2014-03-10 ES ES14717266.2T patent/ES2662108T3/es active Active
-
2015
- 2015-09-02 ZA ZA2015/06441A patent/ZA201506441B/en unknown
-
2017
- 2017-02-16 US US15/434,738 patent/US9945875B2/en active Active
-
2018
- 2018-03-02 US US15/910,108 patent/US10359435B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2662108T3 (es) | 2018-04-05 |
| BR122019026188B1 (pt) | 2024-01-02 |
| US20140303018A1 (en) | 2014-10-09 |
| EP3296747B1 (en) | 2020-01-08 |
| HK1220251A1 (en) | 2017-04-28 |
| EP3660512A1 (en) | 2020-06-03 |
| BR112015021992A8 (pt) | 2019-12-03 |
| CN108957006B (zh) | 2021-07-27 |
| US9945875B2 (en) | 2018-04-17 |
| WO2014150198A3 (en) | 2014-12-18 |
| BR122019026188A8 (pt) | 2022-10-18 |
| US20180259537A1 (en) | 2018-09-13 |
| BR122019026188A2 (https=) | 2017-07-18 |
| WO2014150198A2 (en) | 2014-09-25 |
| ES2986657T3 (es) | 2024-11-12 |
| CN105143887B (zh) | 2018-08-28 |
| ZA201506441B (en) | 2019-07-31 |
| CN105143887A (zh) | 2015-12-09 |
| US10359435B2 (en) | 2019-07-23 |
| EP3660512C0 (en) | 2024-07-24 |
| EP3296747A1 (en) | 2018-03-21 |
| BR112015021992A2 (pt) | 2017-07-18 |
| ES2773999T3 (es) | 2020-07-16 |
| MX360140B (es) | 2018-10-24 |
| US20170227550A1 (en) | 2017-08-10 |
| EP2972386B1 (en) | 2018-01-10 |
| MX2015011756A (es) | 2016-01-14 |
| EP2972386A2 (en) | 2016-01-20 |
| EP3660512B1 (en) | 2024-07-24 |
| DK3296747T3 (da) | 2020-03-30 |
| CN108957006A (zh) | 2018-12-07 |
| US9612248B2 (en) | 2017-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX387719B (es) | Biomarcadores de la enfermedad del hígado graso no alcohólico (nafld) y la esteatohepatitis no alcohólica (nash) y usos de estos. | |
| CL2016002455A1 (es) | Anticuerpos multiespecíficos. | |
| AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| GEAP202114450A (en) | Anti-tigit antibodies | |
| HUE053457T2 (hu) | Multispecifikus ellenanyag-konstrukciók | |
| PL3261651T3 (pl) | Chimeryczne receptory antygenowe (car) ukierunkowane na nowotwory złośliwe układu krwiotwórczego, kompozycje i sposoby ich stosowania | |
| UY34601A (es) | ?mezclas fungicidas de pirazol?. | |
| GEAP202114453A (en) | Anti-lag3 antibodies and antigen-binding fragments | |
| EP4282983A3 (en) | Compositions and methods for polynucleotide sequencing | |
| MX387296B (es) | Proliferacion ex vivo de celulas epiteliales. | |
| BR112017003414A2 (pt) | composições compreendendo caseína e métodos para produzir as mesmas | |
| EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
| MX2016012667A (es) | Composiciones y metodos relacionados con el diagnostico de cancer de prostata. | |
| CL2016000351A1 (es) | Método para la cuantificación de actinio-227 en composiciones de radio-223. | |
| MX392040B (es) | Estandares de antigeno prostatico y sus usos. | |
| EA201690263A1 (ru) | Улучшенные способы получения перампанеля | |
| IN2013MU01113A (https=) | ||
| MX2017010901A (es) | Colorantes de acido trisazo. | |
| BR112017014842A2 (pt) | composição de agente de formação de imagem, kit de agente de formação de imagem, e, método para preparação de uma composição de agente de formação de imagem | |
| MX2015012523A (es) | Metodos para elaborar composiciones antineoplasicas. | |
| TH1601003614A (th) | การทดสอบวินิจฉัยโรคซึ่งถูกปรับปรุงสำหรับแอนทิบอดี csfv | |
| BR112018014842A2 (pt) | biomarcadores de doenças hepática gordurosa não alcoólica (nafld) e esteato-hepatite não alcoólica (nash) e utilização dos mesmos | |
| TWD162428S (zh) | 鞋墊 | |
| TWD175566S (zh) | 雪鏡 |